Daniel C. Cho, Thomas E. Hutson, Wolfram Samlowski, Peter Sportelli, Brad Somer, Paul Richards, Jeffrey A. Sosman, Igor Puzanov, M. Dror Michaelson, Keith T. Flaherty, Robert A. Figlin and Nicholas J. Vogelzang Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy Cancer 118
Article first published online: 6 JUN 2012 | DOI: 10.1002/cncr.27668
The novel Akt inhibitor perifosine demonstrates single-agent activity in patients with advanced renal cell carcinoma who have failed on vascular endothelial growth factor-targeted therapy. Perifosine is worthy of further investigation in renal cancer, particularly in combination with other molecularly targeted agents.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field